Shares of Exscientia plc (NASDAQ:EXAI – Get Rating) traded down 5.3% during mid-day trading on Friday . The stock traded as low as $5.02 and last traded at $5.02. 25,964 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 303,529 shares. The stock had previously closed at $5.30.
Analysts Set New Price Targets
Separately, Morgan Stanley dropped their price target on Exscientia from $15.00 to $14.00 and set an “equal weight” rating for the company in a research note on Monday, April 10th.
Exscientia Stock Performance
The company has a market cap of $632.24 million, a PE ratio of -3.74 and a beta of 0.38. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.04 and a current ratio of 6.05. The company’s 50 day moving average price is $5.64 and its 200-day moving average price is $6.12.
Institutional Investors Weigh In On Exscientia
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its position in shares of Exscientia by 65.5% during the 4th quarter. Bank of America Corp DE now owns 5,092 shares of the company’s stock valued at $27,000 after purchasing an additional 2,015 shares during the period. UBS Group AG boosted its holdings in shares of Exscientia by 2,269.3% in the 4th quarter. UBS Group AG now owns 7,108 shares of the company’s stock valued at $38,000 after acquiring an additional 6,808 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Exscientia by 110.0% in the 1st quarter. Tower Research Capital LLC TRC now owns 9,992 shares of the company’s stock valued at $53,000 after acquiring an additional 5,233 shares during the last quarter. Citigroup Inc. lifted its holdings in Exscientia by 127.2% during the fourth quarter. Citigroup Inc. now owns 11,910 shares of the company’s stock valued at $63,000 after purchasing an additional 6,669 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Exscientia during the first quarter valued at $85,000. Hedge funds and other institutional investors own 22.36% of the company’s stock.
Exscientia Company Profile
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection.
- Get a free copy of the StockNews.com research report on Exscientia (EXAI)
- MarketBeat Week in Review – 5/8 – 5/12
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.